Niche-based screening identifies small-molecule inhibitors of leukemia stem cells

Article metrics

Abstract

Efforts to develop more effective therapies for acute leukemia may benefit from high-throughput screening systems that reflect the complex physiology of the disease, including leukemia stem cells (LSCs) and supportive interactions with the bone marrow microenvironment. The therapeutic targeting of LSCs is challenging because LSCs are highly similar to normal hematopoietic stem and progenitor cells (HSPCs) and are protected by stromal cells in vivo. We screened 14,718 compounds in a leukemia-stroma co-culture system for inhibition of cobblestone formation, a cellular behavior associated with stem-cell function. Among those compounds that inhibited malignant cells but spared HSPCs was the cholesterol-lowering drug lovastatin. Lovastatin showed anti-LSC activity in vitro and in an in vivo bone marrow transplantation model. Mechanistic studies demonstrated that the effect was on target, via inhibition of HMG-CoA reductase. These results illustrate the power of merging physiologically relevant models with high-throughput screening.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: A high-throughput system for probing LSCe cells within a stromal niche.
Figure 2: New small molecule BRD7116 selectively targets LSCe cells by cell-autonomous and cell-non-autonomous mechanisms.
Figure 3: Lovastatin selectively inhibits mouse and human leukemia cells in co-culture.
Figure 4: Sensitivity of LSCe cells to HMGCR inhibition.

Accession codes

Primary accessions

Gene Expression Omnibus

References

  1. 1

    Konopleva, M., Tabe, Y., Zeng, Z. & Andreeff, M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat. 12, 103–113 (2009).

  2. 2

    McMillin, D.W. et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat. Med. 16, 483–489 (2010).

  3. 3

    Somervaille, T.C. & Cleary, M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 10, 257–268 (2006).

  4. 4

    Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).

  5. 5

    Guzman, M.L. et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98, 2301–2307 (2001).

  6. 6

    Costello, R.T. et al. Human acute myeloid leukemia CD34+/CD38 progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res. 60, 4403–4411 (2000).

  7. 7

    Despeaux, M. et al. Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Leukemia 25, 1789–1793 (2011).

  8. 8

    Krivtsov, A.V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818–822 (2006).

  9. 9

    Plosker, G.L. & Faulds, D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 45, 788–856 (1993).

  10. 10

    Stentoft, J. The toxicity of cytarabine. Drug Saf. 5, 7–27 (1990).

  11. 11

    Terpstra, W. et al. Long-term leukemia-initiating capacity of a CD34 subpopulation of acute myeloid leukemia. Blood 87, 2187–2194 (1996).

  12. 12

    Breems, D.A., Blokland, E.A., Neben, S. & Ploemacher, R.E. Frequency analysis of human primitive haematopoietic stem cell subsets using a cobblestone area forming cell assay. Leukemia 8, 1095–1104 (1994).

  13. 13

    Ploemacher, R.E., van der Sluijs, J.P., van Beurden, C.A., Baert, M.R. & Chan, P.L. Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse. Blood 78, 2527–2533 (1991).

  14. 14

    Corral, J. et al. An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell 85, 853–861 (1996).

  15. 15

    Carpenter, A.E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).

  16. 16

    Jones, T.R. et al. Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc. Natl. Acad. Sci. USA 106, 1826–1831 (2009).

  17. 17

    Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964–1969 (2000).

  18. 18

    Hassane, D.C. et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood 111, 5654–5662 (2008).

  19. 19

    Guzman, M.L. et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood 105, 4163–4169 (2005).

  20. 20

    Guzman, M.L. et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110, 4427–4435 (2007).

  21. 21

    Escuin, D. et al. The hematopoietic-specific β1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression. Cell Cycle 8, 3914–3924 (2009).

  22. 22

    Memon, R.A. et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ–responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141, 4021–4031 (2000).

  23. 23

    Gimble, J.M. et al. Peroxisome proliferator-activated receptor-γ activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol. Pharmacol. 50, 1087–1094 (1996).

  24. 24

    Wolins, N.E. et al. OP9 mouse stromal cells rapidly differentiate into adipocytes: characterization of a useful new model of adipogenesis. J. Lipid Res. 47, 450–460 (2006).

  25. 25

    Naveiras, O. et al. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 460, 259–263 (2009).

  26. 26

    Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).

  27. 27

    Mootha, V.K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).

  28. 28

    Park, D.J., Vuong, P.T., de Vos, S., Douer, D. & Koeffler, H.P. Comparative analysis of genes regulated by PML/RARα and PLZF/RARα in response to retinoic acid using oligonucleotide arrays. Blood 102, 3727–3736 (2003).

  29. 29

    Huntly, B.J. et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6, 587–596 (2004).

  30. 30

    Moore, M.A., Dorn, D.C., Schuringa, J.J., Chung, K.Y. & Morrone, G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp. Hematol. 35, 105–116 (2007).

  31. 31

    Gazzerro, P. et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 64, 102–146 (2012).

  32. 32

    Meacham, C.E., Ho, E.E., Dubrovsky, E., Gertler, F.B. & Hemann, M.T. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nat. Genet. 41, 1133–1137 (2009).

  33. 33

    Luo, B. et al. Highly parallel identification of essential genes in cancer cells. Proc. Natl. Acad. Sci. USA 105, 20380–20385 (2008).

  34. 34

    Konstantinopoulos, P.A. & Papavassiliou, A.G. Multilevel modulation of the mevalonate and protein-prenylation circuitries as a novel strategy for anticancer therapy. Trends Pharmacol. Sci. 28, 6–13 (2007).

  35. 35

    Bellosta, S., Paoletti, R. & Corsini, A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109, III50–III57 (2004).

  36. 36

    Langdon, W.Y. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity. Crit. Rev. Oncog. 17, 199–209 (2012).

  37. 37

    Weiss, R.B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19, 670–686 (1992).

  38. 38

    Gupta, P.B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645–659 (2009).

  39. 39

    Yeh, J.R. et al. Discovering chemical modifiers of oncogene-regulated hematopoietic differentiation. Nat. Chem. Biol. 5, 236–243 (2009).

  40. 40

    Sachlos, E. et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149, 1284–1297 (2012).

  41. 41

    Dimitroulakos, J. et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93, 1308–1318 (1999).

  42. 42

    Li, H.Y., Appelbaum, F.R., Willman, C.L., Zager, R.A. & Banker, D.E. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 101, 3628–3634 (2003).

  43. 43

    Osmak, M. Statins and cancer: current and future prospects. Cancer Lett. 324, 1–12 (2012).

  44. 44

    Kornblau, S.M. et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study. Blood 109, 2999–3006 (2007).

  45. 45

    Williams, A.B. et al. Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood 120, 3069–3079 (2012).

  46. 46

    Nielsen, S.F., Nordestgaard, B.G. & Bojesen, S.E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 367, 1792–1802 (2012).

  47. 47

    Whyte, D.B. et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459–14464 (1997).

  48. 48

    Rowell, C.A., Kowalczyk, J.J., Lewis, M.D. & Garcia, A.M. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. J. Biol. Chem. 272, 14093–14097 (1997).

  49. 49

    Berndt, N., Hamilton, A.D. & Sebti, S.M. Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775–791 (2011).

  50. 50

    Lobell, R.B. et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 61, 8758–8768 (2001).

  51. 51

    Krivtsov, A.V. et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442, 818–822 (2006).

  52. 52

    Moore, M.A., Dorn, D.C., Schuringa, J.J., Chung, K.Y. & Morrone, G. Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells. Exp. Hematol. 35, 105–116 (2007).

  53. 53

    van Os, R.P., de Haan, G. & Dethmers-Ausema, B. In vitro assays for cobblestone area–forming cells, LTC-IC and CFU-C. Methods Mol. Biol. 430, 143–157 (2008).

  54. 54

    Basu, A. et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 154, 1151–1161 (2013).

Download references

Acknowledgements

We wish to thank L. VerPlank, V. Raksakulthai, A. Liberzon, M. Palmer, G. Cowley, J. Burbank, P. Aspesi Jr., M. Bliss-Moreau, D. Barker, B. Wagner, A. Krivtsov, S.A. Armstrong, R. Karmacharya, J. Perez, R. Onofrio, D. Thomas, R. Busanelli, D. Auclair, K. Masson, J. Du, C. Moore, M. Kharas, Y. Hoshida, D. Bachovchin, A. Mullally, J. Grabarek, A. Fraser, A. Basu, J. Cheah, N. Bodycombe, C. Mulrooney, S. Johnston, G. Walzer, D. Wilpitz, A. Bracha, A. Fabian, C. Hon, J. McGrath, C. Hartland, M. Hickey, T.R. Jones, M. Bray, K. Sokolnicki, R. Okabe, M. Paktinat, M. McConkey, L. Gaffney, L. Solomon, K. Rose and Broad Compound Management. We also thank the Golub, Gilliland and Ebert laboratories for scientific discussions and technical expertise. This work was funded by grants from the Starr Cancer Consortium (SCC Award l1-A50), the US National Institutes of Health (U54CA112962, U01HL1004402, T32 HL007623, T32 GM007753, N01-CO-12400, R01 GM089652, RL1CA133834, 20XS139, RL1HG004671, RL1CA133834, RL1GM084437 and UL1RR024924) and the US National Science Foundation (DBI 1148823). The content of this publication is solely the responsibility of the authors and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government. T.R.G., D.G.G. and S.L.S. are investigators at the Howard Hughes Medical Institute.

Author information

A.E.C., A.F.S., A.L.S., A.M.S., B.L.E., D.G.G., D.T.S., K.A.H., M.A.S.M., P.G.M., S.L.S., S.M. and T.R.G. designed the project strategy and interpreted results. A.E.C., A.L.S., A.M.S., D.G.G., D.J.L., D.T.S., J.A.B., J.E.H., J.M.N., K.A.H., N.J.T., P.G.M., S.L.S., S.M., S.S., T.H., T.K. and Z.T. developed the assay. A.L.S., D.J.L., J.A.B., J.M.N., K.A.H., M. Duvet, N.J.T., P.A.C., P.G.M., S.C., S.S. and T.H. conducted small-molecule screening. A.L.S., A.R.K., B.M., C.H., D.J.L., D.P.S., F.A.-S., J.A.B., J.H.S., J.M.N., K.A.H., L.P.C., M. Dai, M. Duvet, M.J., N.J.T., P.G.M., R.N., R.P., S.C., S.S., T.H. and V.D. conducted follow-up studies. A.M.S., B.L.E., K.A.H., P.G.M. and T.R.G. drafted the paper.

Correspondence to Malcolm A S Moore or David T Scadden or Stuart L Schreiber or Benjamin L Ebert or Todd R Golub.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Results, Supplementary Figures 1–5, Supplementary Tables 1–8 and Supplementary Note 1. (PDF 6375 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hartwell, K., Miller, P., Mukherjee, S. et al. Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol 9, 840–848 (2013) doi:10.1038/nchembio.1367

Download citation

Further reading